Krebs Biochemicals & Industries (BOM:524518) Debt-to-Equity : N/A (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Krebs Biochemicals & Industries Debt-to-Equity?

Krebs Biochemicals & Industries's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0.0 Mil. Krebs Biochemicals & Industries's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0.0 Mil. Krebs Biochemicals & Industries's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₹0.0 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Krebs Biochemicals & Industries's Debt-to-Equity or its related term are showing as below:

BOM:524518' s Debt-to-Equity Range Over the Past 10 Years
Min: -6.59 Med: -2.14 Max: 32.19
Current: -1.73

During the past 13 years, the highest Debt-to-Equity Ratio of Krebs Biochemicals & Industries was 32.19. The lowest was -6.59. And the median was -2.14.

BOM:524518's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.29 vs BOM:524518: -1.73

Krebs Biochemicals & Industries Debt-to-Equity Historical Data

The historical data trend for Krebs Biochemicals & Industries's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Krebs Biochemicals & Industries Debt-to-Equity Chart

Krebs Biochemicals & Industries Annual Data

Trend

Mar12

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Equity

Get a 7-Day Free Trial

-6.59

-3.25

-2.95

-2.51

-2.30

Krebs Biochemicals & Industries Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															N/A	-2.30	N/A	-1.73	N/A

Competitive Comparison of Krebs Biochemicals & Industries's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Krebs Biochemicals & Industries's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Krebs Biochemicals & Industries's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Krebs Biochemicals & Industries's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Krebs Biochemicals & Industries's Debt-to-Equity falls into.

Krebs Biochemicals & Industries Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Krebs Biochemicals & Industries's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(101.239	+	2182.465)	/	-994.623
	=	-2.30

Krebs Biochemicals & Industries's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	0
	=	N/A

Krebs Biochemicals & Industries (BOM:524518) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Krebs Biochemicals & Industries Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Krebs Biochemicals & Industries's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Krebs Biochemicals & Industries (BOM:524518) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Krebs Biochemicals & Industries Ltd (BOM:524518) » Definitions » Debt-to-Equity

Traded in Other Exchanges

KREBSBIO:India

Address

Road No. 8, Banjara Hills, 8-2-577/B, Plot No. 34, 3rd Floor, Maas Heights, Hyderabad, TG, IND, 500 034

Website

http://www.krebsbiochem.com

Krebs Biochemicals & Industries Ltd is a biochemical company in India. It is engaged in the business of manufacture of active pharmaceutical ingredients. It has two manufacturing plants in Andhra Pradesh, India - one in Nellore and one in Vizag both Units are equipped for chemical synthesis, fermentation, and enzymatic technologies providing Krebs with production capacity.

Krebs Biochemicals & Industries (BOM:524518) Headlines

No Headlines